Research ArticleImmunology

Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance

See allHide authors and affiliations

Science Translational Medicine  18 Feb 2015:
Vol. 7, Issue 275, pp. 275ra21
DOI: 10.1126/scitranslmed.aaa1957

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Can’t we all get along?

The past century brought great advances for the treatment of some genetic disorders caused by single protein deficiencies. In particular, hemophilia A, which is caused by a deficiency of coagulation factor VIII, can now be treated by replacing the missing factor. Unfortunately, the most severely affected patients, who completely lack endogenous factor VIII, often develop antibodies against the replacement protein because their bodies recognize it as a foreign substance. To overcome this problem, Gupta et al. have now developed a method for transplacental exposure of fetuses to the missing antigen, thus ensuring immune tolerance for protein therapy that will be delivered after birth.